On May 19, Coram Infusion Services, the infusion therapy branch of CVS, reported that it was selling infusion services assets to KabaFusion. The transaction includes six locations that serve as pharmacies and ambulatory infusion suites.
KabaFusion, a portfolio company of Novo Holdings, provides acute and home infusion services in more than 40 states, specializing in intravenous immunoglobulin and other home infusion therapies. The company serves patients in 45 states through its nationwide network of home infusion pharmacies, alternative infusion sites and home health agencies.
The transaction will expand KabaFusion’s ability to serve a growing number of patients nationwide and strengthen its commitment to deliver high-quality patient care across a broad range of therapies. The financial terms of the acquisition were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the seventh infusion services acquisition of the year. There were 17 infusions services deals announced in 2024, and seven announced in 2023. It also marks KabaFusion’s first transaction of 2025.
